Immunosuppression
159
20
24
78
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
23 trials with published results (14%)
Research Maturity
78 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.5%
12 terminated out of 159 trials
86.7%
+0.1% vs benchmark
26%
41 trials in Phase 3/4
29%
23 of 78 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 78 completed trials
Clinical Trials (159)
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Immunoinflammatory Regulation of Esketamine in Septic Patients
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
(TNX-1500) in Kidney Transplant Recipients
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
Vascularized Composite Bladder Allograft Transplantation
NAI for Sepsis With Persistent Lymphopenia
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)
Combined Immunosuppression for Pediatric Crohn's Disease
Adaptation of Lung Transplant Recipients at Extreme Altitude
HLA-Identical Sibling Renal Transplant Tolerance
Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation
Torque Teno Virus: A Biomarker of Immunosuppression
Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Pathological Myeloid Activation After Sepsis and Trauma